Biology Based Cancer Interception
|
|
|
- Ralf Gibson
- 6 years ago
- Views:
Transcription
1 Biology Based Cancer Interception Waun Ki Hong, M.D. American Cancer Society Professor Former Head Division of Cancer Medicine UT MD Anderson Cancer Center
2 Disclosures SAB : Janssen,Medimmune,Molecular Health Special Advisor : Omnitura, Enzychem
3 The most important challenge in the cancer chemoprevention field: Rational selection of the most effective and safe agents targeting early molecular drivers of cancer
4 From: Kelloff et al, Clin Cancer Res 2006; 12(12) 3661; June 15, Epithelial Cancer Progression Model Cancer Driver
5 The Path to Cancer - Three Strikes and You re Out New England Journal of Medicine, November 12, 2015
6 Biology and Signaling Pathways of Cancer Hallmarks of Cancer (2011) Sustaining proliferation Evading growth suppression Resisting cell death immor Achieving immortality Identify the short circuit unique to cancer cells Develop targeted therapy against the problem Inducing angiogenesis Invasion & metastasis Tumor Microenvironment Signal Transduction Pathways Hanahan/Weinberg/Hahn
7 Hypothetical Model of Biology and Signaling Pathways of PreCancer Hallmarks of PreCancer??? Resisting cell death Sustaining Proliferation Evading growth suppression Achieving immor Immortalit y Identify the driving circuit that transforms cells? Develop preventive agents to target major driver pathways? Inducing angiogenesi s Hanahan/Weinberg/Hahn Invasion & Metastasi s Tumor Microenvironment? Signal Transduction Pathways?
8 Molecular Heterogeneity Precancer Cancer Easier to target less complex molecula r systems Modified from George Post
9 Understanding Biology of Precancer Cell is the most crucial for the development of target based Interception strategy
10 How we can identify Cancer Drivers that are responsible for malignant progression? And how we can hijack or intercept Cancer Driver?
11 A Strategy for Identifying Early Intercepting Agent Master Molecule affecting all Hallmarks of Cancer cell? Selecting Intercepting agent through Reverse Migration? Immune Targeting Interception?
12 Therapeutic Targeting of Hallmarks of Cancer
13 Aneustat (Master Molecular Switcher?) inhibiting Multiple Targets in All Hallmarks of Cancer Based on Preclinical studies Adapted from: Hallmarks of Cancer: The Next Generation ; Douglas Hanahan & Robert Weinberg, Cell, Vol. 144, , March, Omnitura Therapeutics Inc. Confidential
14 A Strategy for Identifying Early Intercepting Agent Master Molecule affecting all Hallmarks of Cancer cell? Selecting Intercepting agent through Reverse Migration? Immune Targeting Interception?
15 Cancer Interception through Reverse Migration Successful Example: SERMs in Breast Cancer Hijacking Molecular Drivers of Cancer for Prevention Blackburn EH, Cancer Prev Res 2011;4:
16 Reverse Migration of Tamoxifen METASTATIC ADJUVANT Premenopausal patients Metastatic Breast Cancer Oophorectomy Tamoxifen Buchanana RB et al. J Clin Oncol 1986 Fisher B et al. N Engl J Med 1989 PREVENTION Fisher B et al. JNCI 1998
17 Hypotheses of Reverse Migration Strategy Premalignancies share biologic properties with malignancies Effective targeted therapy of advanced cancer may be applicable to adjuvant, even prevention setting Reverse migration from therapy to prevention is scientifically sound, e.g., tamoxifen in breast cancer
18
19 Intercepting agents through Reverse Migration Concept SERM in Breast Cancer Lenalidomide in Multiple Myeloma Hedgehog inhibitor in Basal Cell Carcinoma PARP inhibitors in BRCA-mutation carriers Androgen inhibitor in Prostate Cancer EGFR inhibitor in EGFR mutated NSCLC
20 A Strategy for Identifying Early Intercepting Agent Master Molecule affecting all Hallmarks of Cancer cell? Selecting Intercepting agent through Reverse Migration? Immune Targeting Interception?
21 Immunosuppressive Metastatic Microenvironment
22 Nature 18 November 2015 Immunology: Another shot at cancer Charles Schmidt Targeting the immune system to fight breast cancer was all but dismissed in the 1990s, but the strategy is making a big comeback with the possibility of a breast-cancer vaccine
23 Colon Cancer Colonic Polyp MUC1 Cyclin B1 Lung Cancer Lung neoplasia and metaplasia
24 Malignant Transformation can be blocked and/or Detoured Through Cancer Interception Approach Premalignant cell
25 The Biology Behind Cancer Prevention by Delay 1 Commentary re: J. A. O Shaughnessy et al., Treatment and Prevention of Intraepithelial Neoplasia: An Important Target for Accelerated New Agent Development. Clini. Cancer Res., 8: , Scott M. Lippman and Waun Ki Hong 2
26 Integration GWAS and PCGA Genetic Risk Model as Score Card Identify Highest Risk Cohort Identify Target at the Tissue Level Select Appropriate Intercepting Agent Novel Clinical Design
27 Why has cancer prevention been so challenging, with so few successes in last 10 years? The New York Times, November 13, 20
28 A Strategy for Identifying Early Intercepting Agent Master Molecule affecting all Hallmarks of Cancer cell? Selecting Intercepting agent through Reverse Migration? Immune Targeting Interception?
29 Identify targets for early interventions Cancer Prevention Strategy for Next 10 Years PreCancer Genome Atlas (PCGA) PERSONALIZED TARGETED PREVENTION
30 A Strategy for Identifying Early Intercepting Agent Master Molecule affecting all Hallmarks of Cancer cell? Selecting Intercepting agent through Reverse Migration? Immune Targeting Interception?
31 Is there Intercepting agent affecting all Hallmarks of Cancer Cell as Multivalent Multitargted Agent??
32 Can we identify Intercepting agent through Reverse Migration Fashion from treatment of advanced cancer?
33 What about Immune Targeting Interception Strategy?
34 Vaccines for primary and secondary prevention of non-viral cancers Therapeutic vaccines Given after cancer diagnosis After failure of standard therapy In combination with standard therapy To slow cancer progression or prevent recurrence Preventive vaccines Not yet widely tested Given in the setting of premalignant disease to prevent progression to cancer Expected to be eventually given to individuals at increased cancer risk
The Hallmarks of Cancer
The Hallmarks of Cancer Theresa L. Hodin, Ph.D. Clinical Research Services Theresa.Hodin@RoswellPark.org Hippocrates Cancer surgery, circa 1689 Cancer Surgery Today 1971: Nixon declares War on Cancer
Understanding and Optimizing Treatment of Triple Negative Breast Cancer
Understanding and Optimizing Treatment of Triple Negative Breast Cancer Edith Peterson Mitchell, MD, FACP Clinical Professor of Medicine and Medical Oncology Program Leader, Gastrointestinal Oncology Department
Cancer Genetics. What is Cancer? Cancer Classification. Medical Genetics. Uncontrolled growth of cells. Not all tumors are cancerous
Session8 Medical Genetics Cancer Genetics J avad Jamshidi F a s a U n i v e r s i t y o f M e d i c a l S c i e n c e s, N o v e m b e r 2 0 1 7 What is Cancer? Uncontrolled growth of cells Not all tumors
Introduction. Cancer Biology. Tumor-suppressor genes. Proto-oncogenes. DNA stability genes. Mechanisms of carcinogenesis.
Cancer Biology Chapter 18 Eric J. Hall., Amato Giaccia, Radiobiology for the Radiologist Introduction Tissue homeostasis depends on the regulated cell division and self-elimination (programmed cell death)
Lecture 1: Course Introduction and Cancer ʻby the Numbersʼ. biochemistry 4450a
Lecture 1: Course Introduction and Cancer ʻby the Numbersʼ biochemistry 4450a Introduction Rationale for this course Course ʻPhilosophyʼ Course Outline Evaluation Themes Critical Thinking Cancer ʻby the
Contemporary Classification of Breast Cancer
Contemporary Classification of Breast Cancer Laura C. Collins, M.D. Vice Chair of Anatomic Pathology Professor of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School Boston, MA Outline
OBJECTIVES. 1. List the major hallmarks of cancer. 2. Relate specific genes/proteins to individual hallmarks
OBJECTIVES 1. List the major hallmarks of cancer 2. Relate specific genes/proteins to individual hallmarks 3. Explain how hallmarks of cancer lead to cancer development Case Study 60 year old female Previously
The Challenges of Chemoprevention: How Can We Develop Drugs to Treat Cancer Risk Instead of Metastases?
The Challenges of Chemoprevention: How Can We Develop Drugs to Treat Cancer Risk Instead of Metastases? Moderator: Gary Kelloff, MD, Special Advisor, Division of Cancer Treatment and Diagnosis, National
CELL BIOLOGY - CLUTCH CH CANCER.
!! www.clutchprep.com CONCEPT: OVERVIEW OF CANCER Cancer is a disease which is primarily caused from misregulated cell division, which form There are two types of tumors - Benign tumors remain confined
Index. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Adjuvant therapy, for early-stage triple-negative breast cancer, 740 742 in older early-stage breast cancer patients, 790 795 anti-her2-directed
Pancreatic intraepithelial
Pancreatic intraepithelial neoplasia (PanIN) Markéta Hermanová St. Anne s University Hospital Brno Faculty of Medicine, Masaryk University Precursor lesions of invasive pancreatic cancer Pancreatic intraepithelial
SYSTEMIC THERAPY OPTIONS FOR BREAST CANCER IN 2014
SYSTEMIC THERAPY OPTIONS FOR BREAST Oncology Day 2014 CANCER IN 2014 Dr. Katherine Enright, M.D., M.P.H., F.R.C.P.(C) Katherine.enright@Trilliumhealthpartners.ca OBJECTIVES 1. Outline an approach to the
Cancer Treatment : What s New?
Cancer Treatment : What s New? Dr Angela Pang MBBS (S pore), MRCP (UK), MMed (Spore) Medical Oncology Consultant National University Cancer Institute, Singapore (NCIS) Clinical Care Education Research
Deregulation of signal transduction and cell cycle in Cancer
Deregulation of signal transduction and cell cycle in Cancer Tuangporn Suthiphongchai, Ph.D. Department of Biochemistry Faculty of Science, Mahidol University Email: tuangporn.sut@mahidol.ac.th Room Pr324
Molecular classification of breast cancer implications for pathologists. Sarah E Pinder
Molecular classification of breast cancer implications for pathologists Sarah E Pinder Courtesy of CW Elston Histological types Breast Cancer Special Types 17 morphological special types 25-30% of all
Triple Negative Breast Cancer
Triple Negative Breast Cancer Prof. Dr. Pornchai O-charoenrat Division of Head-Neck & Breast Surgery Department of Surgery Faculty of Medicine Siriraj Hospital Breast Cancer Classification Traditional
Intro to Cancer Therapeutics
An Intro to Cancer Therapeutics Christopher R. Chitambar, MD Professor of Medicine Division of Hematology & Oncology Froedtert and Medical College of Wisconsin Clinical Cancer Center cchitamb@mcw.edu Intro
Lecture 11. Section C (Week 3): Understanding Diseases of the Immune System
Lecture 11 Section C (Week 3): Understanding Diseases of the Immune System 11. Why can t the immune system fight cancer? 12. Understanding immune system function as you get older? 13. How has the immune
Qué hemos aprendido hasta hoy? What have we learned so far?
Qué hemos aprendido hasta hoy? What have we learned so far? Luís Costa Hospital de Santa Maria & Instituto de Medicina Molecular Faculdade de Medicina de Lisboa Disclosures Research Grants: Amgen; Novartis;
Reprogramming Tumor Associated Dendritic Cells for Immunotherapy
Reprogramming Tumor Associated Dendritic Cells for Immunotherapy Edgar Engleman, M.D. Professor of Pathology and Medicine Stanford University Disclosures: Founder of Dendreon, a biotechnology company that
Cancer Prevention. Underlying Assumptions. Other Known Risk Factors. Other Known Risk Factors 6/25/2009
Underlying Assumptions Cancer Prevention Judith A. Luce, M.D. jluce@hemeonc.ucsf.edu The Model of Carcinogenesis Multistep, multiple mutations Takes years: peak annual risk @ 70+ yrs Accelerated by genetic
Molecular Biology of Cancer. Code: ECTS Credits: 6. Degree Type Year Semester
2018/2019 Molecular Biology of Cancer Code: 100863 ECTS Credits: 6 Degree Type Year Semester 2500252 Biochemistry OT 4 0 Contact Name: Carles Arús Caralto Email: Carles.Arus@uab.cat Other comments on languages
Transformation of Normal HMECs (Human Mammary Epithelial Cells) into Metastatic Breast Cancer Cells: Introduction - The Broad Picture:
Transformation of Normal HMECs (Human Mammary Epithelial Cells) into Metastatic Breast Cancer Cells: Introduction - The Broad Picture: Spandana Baruah December, 2016 Cancer is defined as: «A disease caused
6/22/2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017
TARGETING THE TARGETS IN 2017 Primary Care Focus Symposium July 1, 2017 Grace Wang MD I do not have any relevant financial relationships to disclose at this time TARGETING THE TARGETS IN 2017 What are
Johns Hopkins Clinical Update Webinar
Johns Hopkins Clinical Update Webinar Ben Ho Park, M.D., Ph.D. Department of Oncology Johns Hopkins University February 2015 This presentation is the intellectual property of the author/presenter. Contact
Hereditary Breast and Ovarian Cancer Rebecca Sutphen, MD, FACMG
Hereditary Breast and Ovarian Cancer 2015 Rebecca Sutphen, MD, FACMG Among a consecutive series of 11,159 women requesting BRCA testing over one year, 3874 responded to a mailed survey. Most respondents
Breast Cancer Prevention Studies. Key Points. Breast cancer prevention studies are clinical trials (research studies conducted with
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Breast Cancer Prevention
Molecular Biology of Cancer. Code: ECTS Credits: 6. Degree Type Year Semester
2017/2018 Molecular Biology of Cancer Code: 100863 ECTS Credits: 6 Degree Type Year Semester 2500252 Biochemistry OT 4 0 Contact Name: Carles Arús Caralto Email: Carles.Arus@uab.cat Other comments on languages
Cancer Prevention & Control in Adolescent & Young Adult Survivors
+ Cancer Prevention & Control in Adolescent & Young Adult Survivors NCPF Workshop July 15-16, 2013 Patricia A. Ganz, MD UCLA Schools of Medicine & Public Health Jonsson Comprehensive Cancer Center + Overview
Jill Stopfer, MS, CGC Abramson Cancer Center University of Pennsylvania
Jill Stopfer, MS, CGC Abramson Cancer Center University of Pennsylvania Aging Family history Early menarche Late menopause Nulliparity Estrogen / Progesterone use after menopause More than two alcoholic
Breast Cancer Risk Assessment among Bahraini Women. Majida Fikree, MD, MSc* Randah R Hamadeh, BSc, MSc, D Phil (Oxon)**
Bahrain Medical Bulletin, Vol. 35, No.1, March 2013 Breast Cancer Risk Assessment among Bahraini Women Majida Fikree, MD, MSc* Randah R Hamadeh, BSc, MSc, D Phil (Oxon)** Objective: To estimate breast
Study Of Letrozole Extension. Coordinating Group IBCSG IBCSG BIG 1-07
tudy Of Letrozole Extension Coordinating Group IBCSG IBCSG 35-07 BIG 1-07 A phase III trial evaluating the role of continuous letrozole versus intermittent letrozole following 4 to 6 years of prior adjuvant
Endocrine Therapy in Premenopausal Breast Cancer. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology, PA US Oncology
Endocrine Therapy in Premenopausal Breast Cancer Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology, PA US Oncology Ovarian Ablation or Suppression vs. Not in ER + or ER UK Breast Cancer
Mdi Medical Management of Breast Cancer Morbidity and Mortality Aug 13, 2009 Irina Kovatch, PGY3 Introduction Metastatic disease is the principal cause of death from breast cancer Metastatic events often
Antibody-Drug Conjugates in Glioblastoma Multiforme: Finding Ways Forward
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
oncogenes-and- tumour-suppressor-genes)
Special topics in tumor biochemistry oncogenes-and- tumour-suppressor-genes) Speaker: Prof. Jiunn-Jye Chuu E-Mail: jjchuu@mail.stust.edu.tw Genetic Basis of Cancer Cancer-causing mutations Disease of aging
Section D: The Molecular Biology of Cancer
CHAPTER 19 THE ORGANIZATION AND CONTROL OF EUKARYOTIC GENOMES Section D: The Molecular Biology of Cancer 1. Cancer results from genetic changes that affect the cell cycle 2. Oncogene proteins and faulty
PATHOBIOLOGY OF NEOPLASIA
PATHOBIOLOGY OF NEOPLASIA Department of Pathology Gadjah Mada University School of Medicine dr. Harijadi Blok Biomedis, 6 Maret 2009 [12] 3/17/2009 1 The pathobiology of neoplasia Normal cells Malignant
Prostate Cancer in men with germline DNA repair deficiency
Prostate Cancer in men with germline DNA repair deficiency Bruce Montgomery, MD Professor, Medicine and Urology Univ Washington, Fred Hutchinson CRC VA Puget Sound HCS Disclosures Company Tokai, ESSA,
Breast Cancer. Dr. Andres Wiernik 2017
Breast Cancer Dr. Andres Wiernik 2017 Agenda: The Facts! (Epidemiology/Risk Factors) Biological Classification/Phenotypes of Breast Cancer Treatment approach Local Systemic Agenda: The Facts! (Epidemiology/Risk
Breast Cancer Statistics
1 in 8 Breast Cancer Statistics Incidence Mortality Prevalence 2 Breast Cancer Incidence Breast Cancer Mortality Breast Cancer Prevalence ~$100,000 Female Breast Anatomy Breasts consist mainly of fatty
Neoplasia 18 lecture 6. Dr Heyam Awad MD, FRCPath
Neoplasia 18 lecture 6 Dr Heyam Awad MD, FRCPath ILOS 1. understand the role of TGF beta, contact inhibition and APC in tumorigenesis. 2. implement the above knowledge in understanding histopathology reports.
Principles of Cancer Biology and Therapy. Prof Dr Solange Peters, MD, PhD Cancer Center Lausanne Switzerland
Principles of Cancer Biology and Therapy Prof Dr Solange Peters, MD, PhD Cancer Center Lausanne Switzerland Cancer is an umbrella term covering a plethora of conditions characterized by unscheduled and
Biochemistry of Carcinogenesis. Lecture # 35 Alexander N. Koval
Biochemistry of Carcinogenesis Lecture # 35 Alexander N. Koval What is Cancer? The term "cancer" refers to a group of diseases in which cells grow and spread unrestrained throughout the body. It is difficult
Should novel molecular therapies replace old knowledge of clinical tumor biology?
Should novel molecular therapies replace old knowledge of clinical tumor biology? Danai Daliani, M.D. Director, 1 st Oncology Clinic Euroclinic of Athens Cancer Treatments Localized disease Surgery XRT
Acute: Symptoms that start and worsen quickly but do not last over a long period of time.
Cancer Glossary Acute: Symptoms that start and worsen quickly but do not last over a long period of time. Adjuvant therapy: Treatment given after the main treatment. It usually refers to chemotherapy,
Innate Immunity, Inflammation and Cancer
Innate Immunity, Inflammation and Cancer Willem Overwijk, Ph.D. Melanoma Medical Oncology Center for Cancer Immunology Research MD Anderson Cancer Center, Houston, TX SITC/MDACC -6/14/2013 www.allthingsbeautiful.com
So, Who are the appropriate individuals that should consider genetic counseling and genetic testing?
Hello, I m Banu Arun, Professor of Breast Medical Oncology and Co-Director of Clinical Cancer Genetics at the University of Texas MD Anderson Cancer Center. Today I will be discussing with you Hereditary
A holistic approach to targeting breast cancer part II: Micronutrient synergy. Presented by: Dr. Neha Shanker DRRI
A holistic approach to targeting breast cancer part II: Micronutrient synergy Presented by: Dr. Neha Shanker DRRI Overview of the previous webinar In the last presentation we talked about: Increase in
Chemo-endocrine prevention of breast cancer
Chemo-endocrine prevention of breast cancer Andrea DeCensi, MD Division of Medical Oncology Ospedali Galliera, Genova; Division of Cancer Prevention and Genetics, European Institute of Oncology, Milano;
Germline Genetic Testing for Breast Cancer Risk
Kathmandu, Bir Hospital visit, August 2018 Germline Genetic Testing for Breast Cancer Risk Evidence-based Genetic Screening Rodney J. Scott Demography in New South Wales (total population ~ 7,000,000)
Precompetitive Collaboration in Oncology: Imaging Science. Institute of Medicine February 10, Gary J. Kelloff, MD National Cancer Institute
Precompetitive Collaboration in Oncology: Imaging Science Institute of Medicine February 10, 2010 Gary J. Kelloff, MD National Cancer Institute Value Proposition/Benefit for Partners in Public Private
Risk Assessment, Genetics, and Prevention
Risk Assessment, Genetics, and Prevention Katherine D. Crew, MD MS Director, Clinical Breast Cancer Prevention Program Columbia University Medical Center 1 Outline Breast cancer risk factors Hereditary
8/8/2011. PONDERing the Need to TAILOR Adjuvant Chemotherapy in ER+ Node Positive Breast Cancer. Overview
Overview PONDERing the Need to TAILOR Adjuvant in ER+ Node Positive Breast Cancer Jennifer K. Litton, M.D. Assistant Professor The University of Texas M. D. Anderson Cancer Center Using multigene assay
Cancer and Gene Alterations - 1
Cancer and Gene Alterations - 1 Cancer and Gene Alteration As we know, cancer is a disease of unregulated cell growth. Although we looked at some of the features of cancer when we discussed mitosis checkpoints,
Breast Cancer. Excess Estrogen Exposure. Alcohol use + Pytoestrogens? Abortion. Infertility treatment?
Breast Cancer Breast Cancer Excess Estrogen Exposure Nulliparity or late pregnancy + Early menarche + Late menopause + Cystic ovarian disease + External estrogens exposure + Breast Cancer Excess Estrogen
Tumor responses (patients responding/ patients treated)
Table 1. ACT clinical trial tumor responses and toxicities. a Target antigen Cancer(s) Receptor type Tumor responses (patients responding/ patients treated) Immune-mediated toxicities (patients experiencing
Biologics Effects of Targeted Therapeutics
Report on the isbtc Mini-symposium on Biologics Effects of Targeted Therapeutics Michael B. Atkins, MD Beth Israel Deaconess Medical Center Louis Weiner, M.D. Fox Chase Cancer Center Report on the isbtc
IMMUNOTARGET THERAPY: ASPETTI GENERALI
IMMUNOTARGET THERAPY: ASPETTI GENERALI Alessandro Minisini Dipartimento di Oncologia Azienda Ospedaliero Universitaria Udine Verona, 19 settembre 2015 HALLMARKS OF CANCER Douglas Hanahan, Robert A. Weinberg,
Indiana University Hematology Oncology Fellows Research Interest
Coming into fellowship, my interest was in thoracic oncology. I was interested in targeted therapy in lung cancer and immunotherapy. My current research project is looking into combining immunotherapy
Management of BRCA Positive Breast Cancer. Archana Ganaraj, MD February 17, 2018 UPDATE ON WOMEN S HEALTH
Management of BRCA Positive Breast Cancer Archana Ganaraj, MD February 17, 2018 UPDATE ON WOMEN S HEALTH The number of American women who have lost their lives to breast cancer outstrips the total number
BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY
BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY Cancer is a group of more than 100 different diseases that are characterized by uncontrolled cellular growth,
Molecular and Cell Biology of Cancer. Code: ECTS Credits: 6. Degree Type Year Semester Biomedical Sciences OT 4 0
2018/2019 Molecular and Cell Biology of Cancer Code: 101897 ECTS Credits: 6 Degree Type Year Semester 2501230 Biomedical Sciences OT 4 0 Contact Name: Carles Arús Caralto Email: Carles.Arus@uab.cat Other
Curable cancers: Progress in Oncology. Prof.Dilip Kumar Dhar Princicipal & Professor of Medicine MH Samorita Hospital & Medical College, Dhaka.
Curable cancers: Progress in Oncology Prof.Dilip Kumar Dhar Princicipal & Professor of Medicine MH Samorita Hospital & Medical College, Dhaka. Introduction Cancer is one of the leading causes of morbidity
Tumor Immunity and Immunotherapy. Andrew Lichtman M.D., Ph.D. Brigham and Women s Hospital Harvard Medical School
Tumor Immunity and Immunotherapy Andrew Lichtman M.D., Ph.D. Brigham and Women s Hospital Harvard Medical School Lecture Outline Evidence for tumor immunity Types of tumor antigens Generation of anti-tumor
Development of Carcinoma Pathways
The Construction of Genetic Pathway to Colorectal Cancer Moriah Wright, MD Clinical Fellow in Colorectal Surgery Creighton University School of Medicine Management of Colon and Diseases February 23, 2019
Targeting CDK 4/6. Jee Hyun Kim, M.D., Ph.D. Seoul National University College of Medicine
2016.04.30 GBCC Education Symposium Targeting CDK 4/6 Jee Hyun Kim, M.D., Ph.D. Seoul National University College of Medicine Contents Cyclins -CDKs in cell cycle control CDK 4/6 in breast cancer Preclinical
Cancer Research Coordinating Committee Abstracts for Awards Supported Through California Cancer Research Voluntary Tax Contributions
Abstracts for Awards Supported Through California Cancer Research Voluntary Tax Contributions Table of Contents Click on project titles to see full abstracts PI First Name PI Last Name Title Host Campus
Multimedia Appendix 6 Educational Materials Table of Contents. Intervention Educational Materials Audio Script (version 1)
Multimedia Appendix 6 Educational Materials Table of Contents Intervention Educational Materials... 1 Audio Script (version 1)... 1 Text (version 1)... 5 Slides (version 1)... 17 Audio Script (version
Cancer Cell Self Sufficiency in Growth Signals
Name Date Cancer Cell Self Sufficiency in Growth Signals Part 1: Introduction Read the introduction. Draw a flower in the box when finished with this step. RAS Diagram Use the space below the diagram to
Vaccine Therapy for Cancer
Vaccine Therapy for Cancer Lawrence N Shulman, MD Chief Medical Officer Senior Vice President for Medical Affairs Chief, Division of General Oncology Dana-Farber Cancer Institute Disclosures for Lawrence
Dr C K Kwan. Associate Consultant, Queen Elizabeth Hospital, HKSAR Honorary member, Targeted Therapy Team, ICR, UK
HA Convention 2013 Dr C K Kwan MBChB, FRCR, FHKCR, FHKAM, MPM, CPI, MAppMgt(Hlth) Associate Consultant, Queen Elizabeth Hospital, HKSAR Honorary member, Targeted Therapy Team, ICR, UK To personalize cancer
J. Silvio Gutkind, Ph.D. UCSD Moores Cancer Center Basic Science of Premalignancy: Opportunities for Precision Cancer Prevention
J. Silvio Gutkind, Ph.D. UCSD Moores Cancer Center Basic Science of Premalignancy: Opportunities for Precision Cancer Prevention February 3-5, 2016 Lansdowne Resort, Leesburg, VA Chemoprevention Risk Benefit
New Developments in Cancer Treatment. Ian Rabinowitz MD
New Developments in Cancer Treatment Ian Rabinowitz MD Treatment Outline Angiogenesis inhibition Targeted therapy Immunotherapy Personalization of therapy Genomics and cancer Stem cells and cancer Angiogenesis
Pathology of Lobular & Ductal Preneoplasia. Syed A Hoda, MD Weill-Cornell, New York, NY
Pathology of Lobular & Ductal Preneoplasia Syed A Hoda, MD Weill-Cornell, New York, NY Proliferative Epithelial Changes in Breast A wide range of proliferative epithelial changes occur in the breast There
Review of Hallmarks of Prostate Cancer (PCa) Nilgoon Zarei* Keywords: Prostate Cancer (PCa), Hallmarks of Cancer
Article Health Professional Student Journal 2015 2(1) Review of Hallmarks of Prostate Cancer (PCa) Nilgoon Zarei* Abstract: Prostate cancer (PCa) is the most frequently diagnosed noncutaneous malignancy
MIRROR IMAGE MIRROR IMAGE. The future of cancer diagnostics may be closer than it appears
MIRROR IMAGE MIRROR IMAGE The future of cancer diagnostics may be closer than it appears Advanced molecular techniques, fluorescence, and reconstruction of the tumor microenvironment. The many faces of
Multistep nature of cancer development. Cancer genes
Multistep nature of cancer development Phenotypic progression loss of control over cell growth/death (neoplasm) invasiveness (carcinoma) distal spread (metastatic tumor) Genetic progression multiple genetic
TUMOR M ARKERS MARKERS
TUMOR MARKERS M.Shekarabi IUMS Definition Many cancers are associated with the abnormal production of some molecules l which h can be measured in plasma. These molecules are known as tumor markers. A good
Diet, Nutrition, and Cancer Mechanisms The Role of Clinical Trials
AICR / WCRF Annual Research Conference Washington DC Diet, Nutrition, and Cancer Mechanisms The Role of Clinical Trials Steven K. Clinton, MD, PhD November 8, 2013 AICR s 2013 Annual Research Conference
Supplementary Figure 1: Comparison of acgh-based and expression-based CNA analysis of tumors from breast cancer GEMMs.
Supplementary Figure 1: Comparison of acgh-based and expression-based CNA analysis of tumors from breast cancer GEMMs. (a) CNA analysis of expression microarray data obtained from 15 tumors in the SV40Tag
Table S2. Expression of PRMT7 in clinical breast carcinoma samples
Table S2. Expression of PRMT7 in clinical breast carcinoma samples (All data were obtained from cancer microarray database Oncomine.) Analysis type* Analysis Class(number sampels) 1 2 3 4 Correlation (up/down)#
非臨床試験 臨床の立場から 京都大学医学部附属病院戸井雅和
資料 2 2 非臨床試験 臨床の立場から 京都大学医学部附属病院戸井雅和 1 Preclinical studies Therapeutic Window: Efficacy/Toxicity Disease Specificity Subtype Specificity Combination: Concurrent/Sequential Therapeutic situation: Response/
Overview of the core ideas in cancer research
Overview of the core ideas in cancer research Paul Edwards Cancer Research UK Cambridge Institute and Department of Pathology, University of Cambridge This lecture Overview of the ideas that provide the
Breast Cancer and the Heart
Breast Cancer and the Heart Anne H. Blaes, M.D., M.S. Associate Professor University of Minnesota Hematology/Oncology Director, Adult Cancer Survivor Clinic No disclosures Objectives Discuss cardiac complications
Molecular Characterization of Breast Cancer: The Clinical Significance
Molecular Characterization of : The Clinical Significance Shahla Masood, M.D. Professor and Chair Department of Pathology and Laboratory Medicine University of Florida College of Medicine-Jacksonville
Molecular and Cell Biology of Cancer. Code: ECTS Credits: 6. Degree Type Year Semester Biomedical Sciences OT 4 0
2017/2018 Molecular and Cell Biology of Cancer Code: 101897 ECTS Credits: 6 Degree Type Year Semester 2501230 Biomedical Sciences OT 4 0 Contact Name: Carles Arús Caralto Email: Carles.Arus@uab.cat Other
breast and OVARIAN cancer
breast and OVARIAN cancer DR DAVID FENNELLY CONSULTANT MEDICAL ONCOLOGIST ST VINCENT S UNIVERSITY HOSPITAL DUBLIN HOW RELEVANT IS ONCOLOGY IN MEDICINE TODAY? Cancer is the second leading cause of death
Immunohistochemical classification of breast tumours
Immunohistochemical classification of breast tumours Workshop in Diagnostic Immunohistochemistry September 19 th - 21 th 2018 Anne-Vibeke Lænkholm Department of Surgical Pathology, Zealand University Hospital,
ISPOR 4 th Asia Pacific Conference IP2 Gilberto de Lima Lopes
Health Economic Considerations for Personalized Medicine in Asia: Using Genomic Profiling to Guide Treatment Decisions in Early Breast Cancer Gilberto de Lima Lopes, Jr., M.D., M.B.A Assistant Director
What is New in Genetic Testing. Steven D. Shapiro MS, DMD, MD
What is New in Genetic Testing Steven D. Shapiro MS, DMD, MD 18th Annual Primary Care Symposium Financial and Commercial Disclosure I have a no financial or commercial interest in my presentation. 2 Genetic
New Developments in the Treatment of Colorectal Cancer. Jonathan Loree, MD, MS, FRCPC Department of Medical Oncology BC Cancer Vancouver Centre
New Developments in the Treatment of Colorectal Cancer Jonathan Loree, MD, MS, FRCPC Department of Medical Oncology BC Cancer Vancouver Centre Personalized Medicine Currently already part of oncology:
Breast Cancer Carcinogenesis: Mechanisms and Pathways in Hormone Receptor Positive Disease
Breast Cancer Carcinogenesis: Mechanisms and Pathways in Hormone Receptor Positive Disease 1 Nearly Two-Thirds of Metastatic Breast Cancers Express Hormone Receptors Breast cancer tumors are often classified
Prof. R. V. Skibbens. Cell Cycle, Cell Division and Cancer (Part 2)
Prof. R. V. Skibbens November 22, 2010 BIOS 10: BioScience in the 21 st Century Cell Cycle, Cell Division and Cancer (Part 2) Directionality - clocks go in only one direction G1 doesn t have replication-inducing
SOFTly: The Long Natural History of [Trials for] [premenopausal] ER+ Breast Cancer
![SOFTly: The Long Natural History of [Trials for] [premenopausal] ER+ Breast Cancer](/thumbs/95/125806264.jpg "SOFTly: The Long Natural History of [Trials for] [premenopausal] ER+ Breast Cancer")
SOFTly: The Long Natural History of [Trials for] [premenopausal] ER+ Breast Cancer Charles Moertel Lecture May 12, 2017 Gini Fleming Charles Moertel Founder of NCCTG Dedication to high quality clinical
Manejo do câncer de mama RH+ na adjuvância: o que há de novo?
II Simpósio Internacional de Câncer de Mama para o Oncologista Clínico Manejo do câncer de mama RH+ na adjuvância: o que há de novo? INGRID A. MAYER, MD, MSCI Assistant Professor of Medicine Director,
Neoplasia 2018 lecture 4. Dr Heyam Awad MD, FRCPath
Neoplasia 2018 lecture 4 Dr Heyam Awad MD, FRCPath ILOS To understand the concept of the hallmarks of cancer and that they are phenotypic changes needed in all cancer cells. To list the tumor enablers
Exploring Immunotherapies: Beyond Checkpoint Inhibitors
Exploring Immunotherapies: Beyond Checkpoint Inhibitors Authored by: Jennifer Dolan Fox, PhD VirtualScopics (Now part of BioTelemetry Research) jennifer_fox@virtualscopics.com +1 585 249 6231 Introduction
Practice of Medicine-1 Ovarian Cancer Clinical Correlation
Practice of Medicine-1 Ovarian Cancer Clinical Correlation Amir A. Jazaeri, M.D. Assistant Professor, Division of Gynecologic Oncology American Cancer Society Female Cancers 2000 Statistics Reprinted by
Summary of Evolution and the Requirements for the Specific Cure of Cancer
Summary of Evolution and the Requirements for the Specific Cure of Cancer The definition of cancer Cancer is defined by malignant behavior, (e.g. cell proliferation and invasiveness in an abnormal context.